BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

755 related articles for article (PubMed ID: 8984692)

  • 1. [Current status of the clinical application of hematopoietic growth factors in oncology].
    Karthaus M; Ganser A
    Ther Umsch; 1996 Nov; 53(11):863-73. PubMed ID: 8984692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current status of clinical indications for hematopoietic growth factors after chemo-/radiotherapy in gynecology].
    Karthaus M; Ganser A
    Zentralbl Gynakol; 1997; 119(12):585-96. PubMed ID: 9483809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of myelodysplastic syndromes with hematopoietic growth factors.
    Ganser A; Hoelzer D
    Hematol Oncol Clin North Am; 1992 Jun; 6(3):633-53. PubMed ID: 1377194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
    Hiddemann W; Wörmann B; Reuter C; Schleyer E; Zühlsdorf M; Böckmann A; Büchner T
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):33-8. PubMed ID: 7528449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical use of hematopoietic growth factors.
    Appelbaum FR
    Semin Hematol; 1989 Jul; 26(3 Suppl 3):7-14. PubMed ID: 2477905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hematopoietic tissue growth factors: clinical factors].
    Polli EE; Foa P
    Ann Ital Med Int; 1991; 6(1 Pt 1):69-81. PubMed ID: 1716450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hematopoietic growth factors in the prevention of infections complications in children with hematologic-oncologic diseases].
    Lehrnbecher T
    Klin Padiatr; 2001 Sep; 213 Suppl 1():A88-102. PubMed ID: 11577368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the efficacy and tolerability of recombinant haematopoietic growth factors in bone marrow transplantation.
    Barge AJ
    Bone Marrow Transplant; 1993; 11 Suppl 2():1-11. PubMed ID: 8334433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical applications of recombinant human colony-stimulating factors.
    Klingemann HG
    CMAJ; 1989 Jan; 140(2):137-42. PubMed ID: 2642725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hematopoietic growth factors in primary and therapy-related bone marrow insufficiency].
    Hansen B; Hippe E; Jacobsen GK; Johnsen HE
    Ugeskr Laeger; 1992 Jun; 154(24):1697-702. PubMed ID: 1378668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical use of granulocyte colony stimulating-factors (GM-CSF and G-CSF].
    Borota R; Borota J; Belić A; Gebauer E; Stefanović N
    Med Pregl; 1997; 50(3-4):87-93. PubMed ID: 9229690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome.
    Herrmann F; Mertelsmann R; Lindemann A; Ottmann OG; Seipelt G; Oster W; Hoelzer D; Ganser A
    Biotechnol Ther; 1991; 2(3-4):299-311. PubMed ID: 1845132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G-CSF and GM-CSF in clinical trials.
    Antman KH
    Yale J Biol Med; 1990; 63(5):387-410. PubMed ID: 1705737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical application of hematopoietic growth factor (IL-3, G-CSF, GM-CSF, and EPO)].
    Motoyoshi K
    Nihon Rinsho; 1992 Aug; 50(8):1967-72. PubMed ID: 1279240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of hematopoietic growth factors in the treatment of neoplastic diseases.
    St Onge J; Jacobson RJ
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):53-63. PubMed ID: 1380737
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colony stimulating factors.
    Klingemann HG; Eaves CJ
    Bone Marrow Transplant; 1988 May; 3(3):177-84. PubMed ID: 2458788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.